On September 3, 2026 BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, reported that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr. Cui and other members of the management team will be available for one-on-one meetings.
Conference: 8th Annual RAS-Targeted Drug Development Summit
Location: The Colonnade Hotel, Boston
Date: Thursday, September 10
Time: 10:00 am Pacific Time | 1:00 pm Eastern Time
Conference: H.C. Wainwright 28th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, Holmes Room II, 4th Floor, New York City
Date: Tuesday, September 15
Time: 7:30 am Pacific Time | 10:30 am Eastern Time
Webcast access for the H.C. Wainwright conference will be available on the Investor Relations section of the company’s website. An archived replay will be available for 90 days.
(Press release, BlossomHill Therapeutics, SEP 3, 2026, https://www.globenewswire.com/news-release/2026/09/03/3355752/0/en/blossomhill-therapeutics-to-present-at-the-8th-annual-ras-targeted-drug-development-summit-h-c-wainwright-28th-annual-global-investment-conference.html [SID1234670590])